查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016411

癌症診斷市場報告：按產品、技術、應用、最終用戶和地區分類（2026-2034 年）

Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球癌症診斷市場規模達2,180億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以4.68%的複合年成長率成長，到2034年達到3,333億美元。北美憑藉其先進的醫療基礎設施、大量的研發投入、廣泛的技術應用以及強力的監管支持，正引領著癌症診斷市場的發展。推動市場成長的關鍵因素包括：人們對早期疾病檢測意識的提高、生活方式改變和遺傳易感性導致的癌症發病率上升，以及診斷技術的進步如何改善患者照護。

市場規模及預測：

  • 預計到2025年，癌症診斷市場價值將達到2,180億美元。
  • 預計從 2026 年到 2034 年，該產業將以 4.68% 的複合年成長率成長，到 2034 年將達到 3,333 億美元。

主要部分：

  • 產品：耗材（抗體、試劑盒和試劑、探針等）是癌症診斷檢測的重要組成部分。它們憑藉其獨特的化學和生物學特性，確保檢測結果的準確性和一致性。儀器（病理儀器、成像儀器、切片檢查儀器）是先進的工具，能夠識別和檢查各個階段的癌症。它們提供準確、全面的信息，對於精準診斷和製定治療策略至關重要。
  • 技術：診斷影像技術[磁振造影(MRI)、電腦斷層掃描 (CT)、正子斷層掃描 (PET)、乳房X光攝影和超音波]透過提供腫瘤的詳細非侵入性影像，正在推動癌症診斷市場的發展。這使得早期發現、準確診斷和密切追蹤疾病進展可能，從而改善臨床決策並提升患者照護。因此，這些技術正被廣泛應用並推動市場擴張。
  • 應用領域：乳癌因其高發病率和早期檢測的重要性，佔據了最大的市場佔有率。先進的診斷技術能夠實現精準檢測和後續觀察，從而支持高效的治療方案。這種對治療的重視改善了患者的預後，並推動了相關診斷技術的大量投資。
  • 終端使用者：醫院和診所是最大的使用者群體，因為它們能夠為廣泛的患者群體提供醫療服務、先進的診斷技術和全面的護理。這些機構完善的醫療保健系統及其對先進技術的持續投入，使得癌症的快速有效識別成為可能，從而創造了巨大的市場需求。
  • 區域：北美憑藉其先進的醫療保健體系、雄厚的研發資源、高昂的醫療費用支出以及尖端診斷技術的廣泛應用，在癌症診斷市場佔據領先地位。此外，該地區還受益於良好的法規環境和完善的醫療服務提供者及機構網路。

主要企業：

  • 癌症診斷市場的主要企業包括 Abbott Laboratories、Agilent Technologies、Becton Dickinson & Company、BioMérieux、Bio-Rad Laboratories、F. Hoffmann-La Roche、GE Healthcare、Hologic、Illumina、Royal Phillips、Kyagen、Quest Diagtics、Siemens Healthnosine） (Siemens Health Sciificent)。

市場成長的主要促進因素：

  • 人工智慧（AI）融合：人工智慧（AI）與數位平台的融合正在透過提高診斷準確率、加快分析速度和增強即時監測，徹底改變癌症診斷方式。這些技術透過簡化數據分析、最大限度地減少人為錯誤和支持臨床決策，顯著提高了診斷效率和患者照護效果。
  • 對微創診斷程序的需求：微創技術的日益普及推動了市場成長，其優勢包括減輕患者不適、降低併發症風險和縮短恢復時間。這些方法提高了診斷準確性和患者滿意度，加速了用於更安全、更有效的癌症檢測的專用儀器的研發。
  • 行動診斷服務的興起：行動診斷服務正在擴大偏遠和醫療資源匱乏地區癌症篩檢的覆蓋範圍。這些移動診療車減少了地理障礙，實現了早期發現和快速治療。透過提高醫療服務的公平性和可近性，它們在當地的癌症管理舉措中發揮著至關重要的作用。
  • 隨著老齡化社會的發展，老年人需要持續的評估和後續觀察，醫療保健系統正在投入資源開發便捷易用的診斷解決方案。這種人口結構的變化正在創造持續的市場需求，並推動老年護理領域的創新。
  • 診斷工具的進步：影像、分子技術和生物標記評估等診斷技術的不斷進步，使得檢測速度更快、精度更高，並為以患者為中心的治療方案提供了依據。這些進步正在加速其在醫療保健系統中的應用，並增強了有效管理複雜癌症病例所需的診斷能力。
  • 醫療基礎設施不斷完善：全球醫療衛生體系，尤其是在開發中國家，正在加強，癌症診斷的普及程度也不斷提高。先進醫療設施的普及、公共衛生政策的進步以及早期檢測意識的增強，都在推動診斷技術的推廣應用。

未來展望：

  • 強勁成長前景：癌症診斷市場預計將迎來強勁成長，這主要得益於技術的不斷進步、對早期檢測需求的不斷成長、醫療基礎設施的不斷完善以及患者和醫護人員意識提升。這些因素共同推動了市場的持續擴張和診斷解決方案的創新。
  • 市場演變：癌症診斷市場正透過整合先進技術和個人化醫療方法而快速發展。準確性、效率和可及性的不斷提升增強了診斷能力，從而改善了患者預後，並推動了醫療保健行業的持續成長和轉型。

隨著人口老化和文明病風險的增加，早期發現對於成功治療至關重要，因此，對尖端篩檢技術和資源的投資也在增加，以應對日益沉重的疾病負擔。此外，分子診斷、影像技術和生物標記識別的進步正在提高癌症檢測的準確性和速度。這些進步使得早期發現、疾病進展追蹤和個人化治療策略成為可能，提高了診斷過程的效率和可靠性，並促進了市場成長。同時，公共衛生計劃和政府資助的篩檢計畫正在提高人們對早期癌症檢測重要性的認知。隨著越來越多的人接受定期體檢，對診斷設備的需求也不斷成長。這些努力極大地促進了早期診斷，提高了患者的生存率，並支持了市場成長。

癌症診斷市場的發展趨勢：

人工智慧與數位科技的融合

將人工智慧和數位技術融入癌症診斷以提升其功能性，正在推動市場成長。人工智慧演算法能夠改善影像分析、模式識別和資料解讀，從而實現更快、更準確的診斷。數位平台透過強化資料管理、實現遠距離診斷和即時監測，提高了效率和可近性。這些技術還有助於整合包括影像和基因組數據在內的各種資料來源，從而產生全面的診斷資訊。人工智慧工具的使用透過最大限度地減少人為錯誤和輔助臨床醫生決策，提高了癌症治療的整體水準。隨著醫療保健系統逐步實現數位轉型，對人工智慧診斷解決方案的需求不斷成長，推動了癌症診斷領域的進一步創新和發展。例如，總部位於蒙特婁的Avita公司於2025年推出了一款人工智慧癌症診斷平台，並在PacBridge Capital Partners的支持下完成了500萬美元的種子輪融資。該平台基於已倒閉的Imagia Canexia公司的資產構建，利用機器學習（ML）和次世代定序技術，實現了更快、更經濟高效的癌症檢測。

對微創診斷方法的需求日益成長

在癌症治療領域，微創診斷技術正日益受到重視。與傳統的侵入性方法相比，微創技術具有許多優勢，包括最大限度地減少患者不適、降低併發症風險、縮短恢復時間、減少住院次數。這些優勢在腫瘤學領域尤其重要，因為患者的安全、舒適和快速診斷至關重要。微創技術通常利用先進的工具和成像技術，以實現更精確的腫瘤定位、識別和表徵。醫療專業人員尋求更有效、更有效率的診斷方案，以及患者傾向於更安全、創傷更小的治療方法，共同推動了這些技術的日益普及。這一趨勢正在加速開發和應用專門用於微創診斷的新型診斷工具，從而改善患者預後，拓展市場機遇，並進一步推動以患者為中心的癌症診斷模式的發展。

農村地區移動診斷服務的興起

移動診斷車在農村和醫療資源匱乏地區的普及是癌症診斷市場成長的關鍵驅動力。這些行動服務透過將必要的篩檢工具直接送到難以獲得固定醫療設施的人群手中，彌補了醫療資源的不足。行動診斷車配備了最先進的診斷設備和訓練有素的醫務人員，能夠早期發現各種癌症，從而促進及時干預並減輕疾病負擔。其移動性使其能夠覆蓋廣泛的區域，包括傳統醫療基礎設施往往匱乏的偏遠和地理位置孤立的地區。例如，2025年2月，杜爾選區的議員肖巴·巴查佈在納西克啟動了一輛癌症診斷車，為農村地區的居民提供口腔癌、乳癌和子宮頸癌篩檢。這輛診斷車配備了醫療設備和獨立的檢查室，並配備了一名牙醫和一名婦科醫生。

癌症診斷市場成長要素：

老年人口增加

全球人口老化是癌症診斷市場成長的主要驅動力。老齡化是多種癌症的既定風險因素，導致老年人對定期診斷篩檢和持續監測的需求不斷增加。隨著預期壽命的延長，越來越多的人需要定期進行癌症篩檢，以確保早期診斷和有效疾病管理。世界衛生組織（WHO）預測，到2030年，全球六分之一的人口將超過60歲，預計2050年，數字將達到21億。面對這些人口結構變化，醫療保健系統需要將資源投入到能夠滿足老年人需求的、便利且先進的診斷技術上。人們對老年醫療保健日益成長的關注正在推動市場成長，這促進了診斷服務的使用，並刺激了專為老年人群設計的微創且易於使用的診斷工具的開發。

診斷工具的進步

癌症診斷市場的發展動力源自於持續的技術創新，這些創新不斷提升診斷流程的準確性、速度和可靠性。分子診斷、影像技術和生物標記辨識的進步，使得各類癌症的檢測和表徵更加精準。這些進步透過揭示腫瘤複雜的遺傳和分子特徵，提高了診斷準確性，並實現了個人化治療。此外，數位化技術和自動化的引入也提高了診斷服務的效率和可近性。 2024年，羅氏擴展了其“數位病理開放環境”，整合了來自八家合作夥伴的20多種先進人工智慧演算法，以增強癌症診斷和個人化治療。這個由人工智慧驅動的平台為病理學家提供了對各種癌症的精準洞察，並改善了患者的治療效果。羅氏的這項措施旨在推動數位病理學的發展，並將創新的人工智慧工具融入日常臨床實踐中。這些創新措施鼓勵醫療專業人員採用先進的診斷技術，從而促進市場擴張，並擴大全球癌症診斷的範圍。

醫療基礎設施擴建

全球醫療基礎設施的擴張，尤其是在新興經濟體，正對市場成長發揮至關重要的作用。配備先進診斷技術的醫療機構的普及，將使更多患者受益於及時的癌症篩檢和精準的診斷。此外，大眾對癌症預防和早期檢測重要性的認知不斷提高，也促使更多人接受診斷檢測。一系列旨在推廣定期篩檢和持續追蹤的公共衛生舉措和宣傳宣傳活動，進一步增強了公眾的這種意識。這些趨勢共同為先進癌症診斷工具的廣泛應用和普及創造了有利環境。這種環境不僅將支撐持續的需求，還將推動市場穩步擴張，並確保不同地區和醫療服務體系的醫療保健效果得到改善。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球癌症診斷市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 消耗品
    • 主要部分
      • 抗體
      • 試劑盒和試劑
      • 探測
      • 其他
  • 裝置
    • 主要部分
      • 病理檢測設備
      • 影像設備
      • 切片檢查器械

第7章 市場區隔：依技術分類

  • 體外診斷檢測
    • 主要部分
      • 聚合酵素鏈鎖反應（PCR）
      • 原位雜合反應（ISH）
      • 免疫組織化學（IHC）
      • 次世代定序（NGS）
      • 微陣列
      • 流式細胞技術
      • 免疫檢測
      • 其他
  • 影像
    • 主要部分
      • 磁振造影（MRI）
      • 電腦斷層掃描（CT）
      • 正子斷層掃描（PET）
      • 乳房X光攝影
      • 超音波
  • 切片檢查方法

第8章 市場區隔：依應用領域分類

  • 乳癌
  • 肺癌
  • 結腸癌
  • 黑色素瘤
  • 其他

第9章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • bioMerieux
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd
    • GE HealthCare
    • Hologic, Inc.
    • Illumina, Inc.
    • Koninklijke Philips NV
    • Qiagen NV
    • Quest Diagnostics
    • Siemens Healthineers AG（Siemens AG）
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A6322

The global cancer diagnostics market size reached USD 218.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 333.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2026-2034. North America leads the cancer diagnostics market owing to advanced healthcare infrastructure, high research investment, widespread technology adoption, and strong regulatory support. The growing awareness about early detection of disease, rising prevalence of cancer due to lifestyle changes and genetic predisposition, and advancements in diagnostics techniques to enhance patient care are some of the major factors propelling the market.

MARKET SIZE & FORECASTS:

  • Cancer diagnostics market was valued at USD 218.0 Billion in 2025.
  • The market is projected to reach USD 333.3 Billion by 2034, at a CAGR of 4.68% from 2026-2034.

DOMINANT SEGMENTS:

  • Products: Consumables (antibodies, kits and reagents, probes, and others) are essential elements that aid in performing cancer diagnostic tests. They guarantee the precision and uniformity of outcomes via their unique chemical and biological characteristics. Instruments (pathology-based instruments, imaging instruments, and biopsy instruments) are advanced tools that allow for the identification and examination of cancer at different stages. They offer exact and comprehensive insights essential for correct diagnosis and treatment strategy.
  • Technology: Imaging [magnetic resonance imaging {MRI}, computed tomography {CT}, positron emission tomography {PET}, mammography, and ultrasound] leads the cancer diagnostics market, as it offers detailed, non-invasive views of tumors. It enables early identification, correct diagnosis, and careful tracking of disease advancement, improving clinical decision-making and enhancing patient care, thus promoting extensive adoption and market expansion.
  • Application: Breast cancer accounts for the largest market share because of its widespread occurrence and the essential requirement for early identification. Sophisticated diagnostic techniques facilitate precise detection and observation, aiding in efficient treatment approaches. This emphasis improves patient results and stimulates significant investment in diagnostic technologies for this purpose.
  • End User: Hospitals and clinics represent the largest segment owing to their wide patient access, sophisticated diagnostic technologies, and capacity to deliver all-encompassing care. Their developed healthcare systems and ongoing investment in advanced technologies facilitate prompt and effective cancer identification, fostering considerable market demand.
  • Region: North America leads the cancer diagnostics market attributed to its sophisticated healthcare system, robust research and development (R&D) resources, significant healthcare spending, and widespread use of cutting-edge diagnostic technologies. The area also gains from favorable regulatory structures and a well-established network of healthcare providers and facilities.

KEY PLAYERS:

  • The leading companies in cancer diagnostics market include Abbott Laboratories, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, GE HealthCare, Hologic, Inc., Illumina, Inc., Koninklijke Philips N.V., Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG (Siemens AG), and Thermo Fisher Scientific Inc.

KEY DRIVERS OF MARKET GROWTH:

  • Integration of Artificial intelligence (AI): The integration of artificial intelligence (AI) and digital platforms is revolutionizing cancer diagnostics through enhanced precision, faster analysis, and facilitating real-time monitoring. These technologies simplify data analysis, minimize human mistakes, and aid in clinical decision-making, greatly improving diagnostic efficiency and patient care results.
  • Demand for Minimally Invasive Diagnostic Procedures: The increasing preference for minimally invasive techniques is bolstering the market growth by providing benefits like decreased patient discomfort, lower risk of complications, and faster recovery times. These methods improve diagnostic accuracy and patient satisfaction, speeding up the creation of specialized instruments that facilitate safer, more effective cancer detection.
  • Rise of Mobile Diagnostic Services: Mobile diagnostic services are increasing availability of cancer screening in isolated and underserved regions. These mobile units lessen geographical obstacles, facilitating early detection and prompt care. By enhancing healthcare equality and access, they play a crucial role in localized cancer management initiatives.
  • Growing Geriatric Population: Elderly people need consistent evaluations and tracking, leading healthcare systems to allocate resources for easy-to-use, accessible diagnostic solutions. This demographic shift fosters ongoing market demand and promotes innovations specifically designed for elderly care.
  • Advancements in Diagnostic Tools: Ongoing advancements in diagnostic technologies, such as imaging, molecular techniques, and biomarker evaluation, are providing quicker, more precise detection and tailored treatment insights. These improvements are promoting higher utilization within healthcare systems and enhancing the diagnostic abilities crucial for effectively managing intricate cancer cases.
  • Expanding Healthcare Infrastructure: Enhanced healthcare systems worldwide, particularly in developing nations, broaden access to cancer diagnostics. Increased access to advanced facilities, public health initiatives, and heightened awareness about early detection results in wider adoption of diagnostic technologies.

FUTURE OUTLOOK:

  • Strong Growth Outlook: The cancer diagnostics market demonstrates a strong growth outlook because of continuous advancements in technology, rising need for early detection, expanding healthcare infrastructure, and increasing awareness among patients and providers. These factors collectively contribute to sustained market expansion and innovation in diagnostic solutions.
  • Market Evolution: The cancer diagnostics market is evolving rapidly with the integration of advanced technologies and personalized medicine approaches. Continuous improvements in accuracy, efficiency, and accessibility are enhancing diagnostic capabilities, thereby enabling better patient outcomes and driving ongoing growth and transformation within the healthcare sector.

With aging populations and increasing lifestyle-related risks, early identification is crucial for successful treatment, leading to investments in cutting-edge screening technologies and resources to address the growing disease burden. Moreover, advances in molecular diagnostics, imaging technologies, and biomarker identification are improving precision and rapidity in cancer detection. These advancements facilitate earlier detection, improved disease tracking, and tailored treatment strategies, enhancing the efficiency and reliability of diagnostic processes, thereby contributing to the market growth. Besides this, public health efforts and government-funded screening programs are raising awareness regarding the early detection of cancer. With an increasing number of people getting routine examinations, the need for diagnostic equipment grows. These initiatives greatly aid in early diagnosis and enhance patient survival rates, supporting the market growth.

CANCER DIAGNOSTICS MARKET TRENDS:

Integration of AI and Digital Technologies

The incorporation of AI and digital technologies into cancer diagnostics to improve functionality is bolstering the market growth. AI algorithms improve image analysis, pattern detection, and data interpretation, resulting in quicker and more precise diagnoses. Digital platforms enhance data management, enable remote diagnostics, and allow real-time monitoring, boosting efficiency and accessibility. These technologies also facilitate the integration of various data sources, including imaging and genomic data, to produce thorough diagnostic insights. The use of AI-driven tools minimizes human mistakes and assists clinicians in their decision-making, thereby enhancing the overall standard of cancer treatment. With healthcare systems progressively adopting digital transformation, the need for AI-enhanced diagnostic solutions rises, fostering additional innovation and growth in the cancer diagnostics sector. For example, in 2025 Montreal-based Avitia launched its AI-powered cancer diagnostics platform and secured a $5 million seed round backed by PacBridge Capital Partners. Built on assets from the defunct Imagia Canexia, the platform uses machine learning (ML) and next-generation sequencing for faster, cost-effective cancer detection.

Growing Demand for Minimally Invasive Diagnostic Procedures

There is an increase in shift towards minimally invasive diagnostic techniques in cancer treatment, which provide several benefits compared to conventional invasive approaches, such as minimized patient discomfort, decreased complication risks, shorter recovery times, and reduced hospital admissions. These advantages are especially crucial in oncology, where patient safety, comfort, and prompt diagnosis are vital. Minimally invasive methods usually employ sophisticated tools and imaging technologies that allow for exact localization, identification, and characterization of tumors with enhanced precision. The increasing acceptance of these procedures is backed by both healthcare professionals, who desire more effective and efficient diagnostic options, and patients, who prefer safer and less invasive approaches. This trend is speeding up the creation and market introduction of novel diagnostic tools tailored for minimally invasive uses, thus improving patient outcomes, broadening market opportunities, and strengthening the shift towards more patient-focused cancer diagnostic methods.

Rise of Mobile Diagnostic Services in Rural Areas

The growing deployment of mobile diagnostic units in rural and underserved regions is a key factor impelling the cancer diagnostics market growth. These mobile services bridge the accessibility gap by bringing essential screening tools directly to populations with limited access to fixed healthcare facilities. Equipped with latest diagnostic tools and trained medical personnel, mobile units enable early detection of various cancers, facilitating timely intervention and reducing disease burden. Their mobility allows for widespread coverage, including remote or geographically isolated areas where traditional healthcare infrastructure is often lacking. For example, in February 2025, Dhule MP Shobha Bachhav flagged off a cancer diagnostic van in Nashik to offer oral, breast, and uterine cancer screenings in rural areas. The van is equipped with medical tools, private exam areas, and staffed by a dentist and gynecologist.

CANCER DIAGNOSTICS MARKET GROWTH DRIVERS:

Increasing Geriatric Population

The increasing elderly population globally is a key factor bolstering the cancer diagnostics market growth. Aging is a well-established risk factor for many types of cancer, resulting in higher demand for regular diagnostic screenings and ongoing monitoring among older adults. With increasing life expectancy, more people need regular cancer screenings to guarantee early diagnosis and efficient disease control. The World Health Organization (WHO) states that by 2030, one out of every six individuals worldwide will be 60 years or older, and this figure is expected to climb to 2.1 billion by 2050. This change in demographics requires healthcare systems to allocate resources for accessible, advanced diagnostic technologies tailored to the needs of older adults. The rising focus on geriatric care support market growth by encouraging more use of diagnostic services and the creation of less invasive, easier-to-use diagnostic tools designed for this demographic.

Advancements in Diagnostic Tools

The market for cancer diagnostics is propelled by ongoing technological innovations that enhance the accuracy, speed, and dependability of diagnostic procedures. Advancements in molecular diagnostics, imaging methods, and biomarker identification facilitate more precise detection and characterization of various cancer types. These advancements improve the precision of diagnoses and enable tailored treatments by uncovering intricate genetic and molecular characteristics of tumors. Moreover, the incorporation of digital technologies and automation enhances the efficiency and availability of diagnostic services. In 2024, Roche expanded its Digital Pathology Open Environment by integrating over 20 advanced AI algorithms from eight collaborators to enhance cancer diagnosis and personalized treatment. This AI-driven platform supported pathologists with precise insights for various cancers, improving patient outcomes. Roche's initiative aimed to advance digital pathology and bring innovative AI tools into routine clinical practice. Such innovative initiatives encourage healthcare professionals to embrace advanced diagnostic technologies, contributing to the market expansion and broadening the scope of cancer diagnostics globally.

Expanding Healthcare Infrastructure

The global expansion of healthcare infrastructure, especially in emerging economies, plays a pivotal role in strengthening the growth of the market. Enhanced access to healthcare facilities equipped with state-of-the-art diagnostic technologies allows a significantly larger patient population to benefit from timely cancer screening and accurate diagnosis. Moreover, increasing awareness regarding cancer prevention and the critical importance of early detection among the general public encourages more individuals to proactively seek diagnostic testing. This growing consciousness is further supported by extensive public health initiatives and educational campaigns aimed at promoting routine screenings and consistent follow-up care. Collectively, these developments establish a favorable environment for the widespread acceptance and integration of advanced cancer diagnostic tools. This environment not only sustains ongoing demand but also facilitates consistent market expansion, ensuring improved healthcare outcomes across various geographic regions and diverse healthcare delivery systems.

CANCER DIAGNOSTICS INDUSTRY SEGMENTATION:

Breakup by Product:

  • Consumables
    • Antibodies
    • Kits and Reagents
    • Probes
    • Others
  • Instruments
    • Pathology-based Instruments
    • Imaging Instruments
    • Biopsy Instruments

Consumables comprise a wide range of products used in the process of cancer diagnostics. These include reagents, test kits, stains, and antibodies that are utilized in various diagnostic procedures, such as immunohistochemistry, molecular testing, and blood-based assays. In addition, consumables play a crucial role in facilitating accurate sample processing, analysis, and interpretation. The rising adoption of consumables due to the increasing demand for diagnostic testing in cancer care is bolstering the growth of the market.

Instruments refer to the equipment and devices employed to perform diagnostic tests and procedures. This category encompasses a diverse range of technologies, such as imaging equipment, laboratory equipment, and diagnostic platforms. Apart from this, there is a rise in the innovation of diagnostic instruments to improve the accuracy, speed, and efficiency of cancer diagnostics.

Breakup by Technology:

  • IVD Testing
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization (ISH)
    • Immunohistochemistry (IHC)
    • Next-generation Sequencing (NGS)
    • Microarrays
    • Flow Cytometry
    • Immunoassays
    • Others
  • Imaging
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET)
    • Mammography
    • Ultrasound
  • Biopsy Technique

Imaging accounts for the majority of the market share

Imaging technologies involve the usage of advanced medical equipment to visualize internal structures and detect abnormalities within the body. Imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, and ultrasound, provide detailed images of tumors and their size, location, and potential metastases. These technologies aid in tumor detection, staging, and treatment monitoring. In line with this, they play a vital role in guiding medical decisions, enabling precise surgical interventions, and evaluating treatment responses.

Breakup by Application:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma

Breast cancer represents the largest market share

Breast cancer diagnostics comprise a wide range of methods for the early detection, diagnosis, and monitoring of breast tumors. Mammography is a widely used imaging technique that aids in detecting abnormalities, such as masses or microcalcifications. Besides this, biopsy procedures, such as core needle and fine-needle biopsies, provide tissue samples for pathological analysis that determine the nature and stage of the tumor. Molecular tests assess specific biomarkers like HER2/neu and estrogen receptor status. In addition, advanced imaging methods, such as breast MRI and molecular breast imaging, offer enhanced visualization and characterization of lesions.

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostic Laboratories

Hospitals and clinics hold the biggest market share

Hospitals serve as comprehensive healthcare institutions that are equipped with advanced diagnostic equipment and expert medical personnel. They offer a wide range of cancer diagnostic services and provide comprehensive treatment planning based on diagnostic findings. On the other hand, clinics involve specialized cancer centers that cater to outpatient needs and often focus exclusively on cancer care. They offer diagnostics, such as mammograms and consultations, which makes it convenient for patients to receive timely evaluations. Both hospitals and clinics play pivotal roles in delivering accurate and efficient diagnostics for cancer patients.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest cancer diagnostics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share due to the improved healthcare infrastructure. Apart from this, the rising focus on early detection of diseases among individuals is contributing to the growth of the market in the region. In line with this, the increasing awareness about cancer, along with favorable reimbursement policies, is propelling the cancer diagnostics market growth. Besides this, the presence of key diagnostic technology manufacturers, research institutions, and a strong network of healthcare facilities is bolstering the growth of the market in the North America region. The cancer diagnostics market revenue is increasing in the region, reflecting the high demand due to advancements in medical technology, increasing cancer prevalence, and the imperative for early and accurate diagnostic procedures

COMPETITIVE LANDSCAPE:

Major players are investing in research and development (R&D) activities to develop innovative diagnostic technologies. This involves exploring new biomarkers, improving imaging modalities, and enhancing the accuracy of molecular and genetic testing methods. In addition, diagnostic companies are continuously updating their existing technologies and platforms and incorporating artificial intelligence (AI) and machine learning (ML) algorithms for more accurate interpretation of diagnostic results. Apart from this, many companies are engaging in collaboration with research institutions, universities, and healthcare providers to gain expert knowledge and can access patient data for validation and improvement of diagnostic tools. Furthermore, key players are introducing new diagnostic products and services that focus on improved sensitivity, specificity, and ease of use.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • bioMerieux
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare
  • Hologic, Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Qiagen N.V.
  • Quest Diagnostics
  • Siemens Healthineers AG (Siemens AG)
  • Thermo Fisher Scientific Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global cancer diagnostics market in 2025?

2. What is the expected growth rate of the global cancer diagnostics market during 2026-2034?

3. What are the key factors driving the global cancer diagnostics market?

4. What has been the impact of COVID-19 on the global cancer diagnostics market?

5. What is the breakup of the global cancer diagnostics market based on the technology?

6. What is the breakup of the global cancer diagnostics market based on the application?

7. What is the breakup of the global cancer diagnostics market based on the end user?

8. What are the key regions in the global cancer diagnostics market?

9. Who are the key players/companies in the global cancer diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Antibodies
      • 6.1.2.2 Kits and Reagents
      • 6.1.2.3 Probes
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Pathology-based Instruments
      • 6.2.2.2 Imaging Instruments
      • 6.2.2.3 Biopsy Instruments
    • 6.2.3 Market Forecast

7 Market Breakup by Technology

  • 7.1 IVD Testing
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Polymerase Chain Reaction (PCR)
      • 7.1.2.2 In Situ Hybridization (ISH)
      • 7.1.2.3 Immunohistochemistry (IHC)
      • 7.1.2.4 Next-generation Sequencing (NGS)
      • 7.1.2.5 Microarrays
      • 7.1.2.6 Flow Cytometry
      • 7.1.2.7 Immunoassays
      • 7.1.2.8 Others
    • 7.1.3 Market Forecast
  • 7.2 Imaging
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Magnetic Resonance Imaging (MRI)
      • 7.2.2.2 Computed Tomography (CT)
      • 7.2.2.3 Positron Emission Tomography (PET)
      • 7.2.2.4 Mammography
      • 7.2.2.5 Ultrasound
    • 7.2.3 Market Forecast
  • 7.3 Biopsy Technique
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Lung Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Colorectal Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Melanoma
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies, Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Becton, Dickinson and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 bioMerieux
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bio-Rad Laboratories, Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 GE HealthCare
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Hologic, Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Illumina, Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Koninklijke Philips N.V.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Qiagen N.V.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Quest Diagnostics
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Siemens Healthineers AG (Siemens AG)
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Thermo Fisher Scientific Inc.
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Diagnostics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Cancer Diagnostics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Cancer Diagnostics Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Cancer Diagnostics Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Cancer Diagnostics Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Cancer Diagnostics Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Cancer Diagnostics Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Cancer Diagnostics (Consumables) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Cancer Diagnostics (Consumables) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Cancer Diagnostics (Instruments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Cancer Diagnostics (Instruments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Cancer Diagnostics (IVD Testing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Cancer Diagnostics (IVD Testing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Cancer Diagnostics (Imaging) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Cancer Diagnostics (Imaging) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Cancer Diagnostics (Biopsy Technique) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Cancer Diagnostics (Biopsy Technique) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Cancer Diagnostics (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Cancer Diagnostics (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Cancer Diagnostics (Lung Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Cancer Diagnostics (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Cancer Diagnostics (Colorectal Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Cancer Diagnostics (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Cancer Diagnostics (Melanoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Cancer Diagnostics (Melanoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Cancer Diagnostics (Other Cancers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Cancer Diagnostics (Other Cancers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Cancer Diagnostics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Cancer Diagnostics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Cancer Diagnostics (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Cancer Diagnostics (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Cancer Diagnostics (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Cancer Diagnostics (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: North America: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: North America: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: United States: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: United States: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Canada: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Canada: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Asia-Pacific: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Asia-Pacific: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: China: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: China: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Japan: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Japan: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: India: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: India: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: South Korea: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: South Korea: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Australia: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Australia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Indonesia: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Indonesia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Europe: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Europe: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Germany: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Germany: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: France: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: France: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: United Kingdom: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: United Kingdom: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Italy: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Italy: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Spain: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Spain: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Russia: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Russia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Latin America: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Latin America: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Brazil: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Brazil: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Mexico: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Mexico: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Middle East and Africa: Cancer Diagnostics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Middle East and Africa: Cancer Diagnostics Market: Breakup by Country (in %), 2025
  • Figure 83: Middle East and Africa: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Global: Cancer Diagnostics Industry: SWOT Analysis
  • Figure 85: Global: Cancer Diagnostics Industry: Value Chain Analysis
  • Figure 86: Global: Cancer Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Diagnostics Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Cancer Diagnostics Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Cancer Diagnostics Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Cancer Diagnostics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Cancer Diagnostics Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Cancer Diagnostics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Cancer Diagnostics Market: Competitive Structure
  • Table 8: Global: Cancer Diagnostics Market: Key Players